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Abstract  
Pre-clinical models often fail to capture the diverse heterogeneity of human malignancies 
and as such lack clinical predictive power. Patient-derived tumour xenografts (PDXs) 
have emerged as a powerful technology: capable of retaining the molecular heterogeneity 
of their originating sample. However, heterogeneity within a tumour is governed by both 
cell-autonomous (e.g. genetic and epigenetic heterogeneity) and non-cell-autonomous 
(e.g. stromal heterogeneity) drivers. Whilst PDXs can largely recapitulate the polygenomic 
architecture of human tumours, they do not fully account for heterogeneity in the tumour 
microenvironment. Hence, these models have substantial utility in basic and translational 
research in cancer biology; but study of stromal or immune drivers of malignant 
progression may be limited. Similarly, PDX models offer the ability to conduct patient 
specific in vivo and ex vivo drug screens, but stromal contributions to treatment responses 
may be under-represented. This review discusses the sources and consequences of 
intratumour heterogeneity and how these are recapitulated in the PDX model. Limitations 
of the current generation of PDXs are discussed and strategies to improve several aspects 
of the model with respect to preserving heterogeneity are proposed.   
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Introduction  
Despite remarkable advances in our understanding of the progression of human 
malignancies and the molecular events that underpin tumour survival, new therapies 
often fail to show significant efficacy in clinical trials. Projects such as The Cancer Genome 
Atlas and METABRIC have demonstrated the remarkable heterogeneity across tumours 
previously believed to be of the same subtype (1). It could be argued that clinical trials fail 
to sufficiently stratify patients based on relevant biomarkers of drug response: the 
response rate of an unscreened population to a molecularly targeted therapy typically lies 
between 10 and 20% (2). Patient stratification based on molecular determinants of drug 
efficacy and tumour heterogeneity allows for significantly greater responses - exemplified 
by the success of ALK kinase inhibitors in EML4-ALK positive non small cell lung cancers 
(3). However, even with patient stratification, clinical responses can be fleeting, often 
adding only 6-12 months before disease progression (2). Thus, understanding 
intertumour heterogeneity is the first step toward improved drug efficacy but cannot fully 
account for tumour relapse.  
 
Intratumour heterogeneity is governed by both cell-autonomous (e.g. genomic and 
epigenomic heterogeneity) and non-cell-autonomous (e.g. stromal heterogeneity) factors. 
This heterogeneity has clinical implications in patient specific responses to therapy and 
the rapid emergence of resistance to targeted therapies (4). By capturing intra as well as 
intertumour heterogeneity, PDX models have a clear advantage over traditional models, 
supporting their use in oncological drug discovery and preclinical development. PDX 
models largely recapitulate cell-autonomous drivers of heterogeneity: exhibiting genomic 
clonal dynamics reminiscent of their originating tumour sample (5,6). Moreover, 
phenotypically distinct isogenic cellular clones have been shown to drive resistance to 
chemotherapy in colorectal PDX models (7). The tumour microenvironment has long been 
known to play an essential role in tumour progression and its role in drug response is 
becoming apparent (8,9). Although PDXs retain the 3D architecture found in human 
tumours, stromal and immune interactions may be altered by inter-species compatibility 
and cellular component deficiencies in host models.  
 
The poor performance of so many investigational drugs suggests preclinical tumour 
models lack clinical predictive power. Indeed, one of the most often cited reasons for 
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clinical failure is a lack of preclinical models that recapitulate the complexity of human 
cancers. It is with this in mind that many research and pharmaceutical groups alike have 
turned to PDX models (10,11). The establishment and predictive power of PDXs has been 
reviewed recently elsewhere (11). This review will focus on the limitations of current 
PDX models and how these can be addressed in the future, specifically in terms of 
maintaining the heterogeneous nature of human cancers (summarized in Table 1). PDXs 
are arguably the best models of tumour heterogeneity, and therefore perhaps the most 
powerful tools for investigating tumour biology. However, they may fail to fully account 
for many non-cell-autonomous drivers of heterogeneity (Figure 1A), and should be 
adapted if they are to reach their full potential as predictors of clinical efficacy in cancer 
drug development.  
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Clonal dynamics and tumour heterogeneity in PDX models  
 
Through the course of tumour initiation and progression, cancerous cells undergo 
repeated mutational events that may or may not result in increased fitness relative to 
neighbouring cells. Dramatic increases in fitness are seen with the acquisition of key 
driver mutations early in a tumours evolution, for example the loss of TP53 may lead to 
clonal dominance. However, selection operates on phenotypes in response to stress 
inducing events, which may be stable or transient (12). A gain of fitness in one clone 
relative to another does not necessarily imply the loss of the latter in favour of the former. 
Rather, clonal populations within the tumour exist dynamically in space and time; 
competing, and perhaps cooperating, to further increase fitness of the tumour population 
as a whole (13) . Clonal dynamics derived from tumours’ inherent heterogeneity are thus 
extremely complex and can play key roles in tumour progression and development.  
 
This conceptual framework of clonal evolution in cancer predicts several clinically 
observable features (14). Firstly, every mutation or copy number aberration (CNA) 
present in the bulk tumour need not be present in all cells; indeed, spatial variation exists 
in a tumour’s clonal composition. The existence of multiple subclones explains variable 
response rates to therapy, even within a single tumour mass, and the rapid emergence of 
drug resistance. For instance, the presence of a minor KRAS mutant clone can predict 
colorectal cancer patients who will develop resistance to epidermal growth factor 
receptor (EGFR) targeted therapy (4).  
 
Our group has previously shown breast cancer consists of at least 10 distinct molecular 
subtypes with significant differences in disease outcome and treatment responses (1). 
Furthermore, we have helped delineate the diverse, variable clonal composition of triple 
negative breast cancers (TNBCs) (15). By allelic frequency measurements of 2,414 
somatic mutations in 104 TNBCs, a complete spectrum of molecular and clonal 
compositions were characterised at diagnosis. Aside from the prognostic features of 
specific rare subclones (4), there is an association between clonal diversity and treatment 
resistance for at least some tumour types – notably ovarian (16) and oesophageal (17). 
Basal-like TNBCs have previously been linked with shorter disease free survival 
compared to non-basal-like TNBCs and tend to be associated with higher clonal diversity 
(15). Furthermore, integration of genomic and drug response data from breast cancer 
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PDX models generated in our lab, show polygenomically engrafted tumours are more 
resistant to therapy than monogenomically engrafted tumours (Bruna et al., (2015) 
manuscript in preparation). Clearly more work is still to be done, but it seems likely that 
the clonal composition of tumours will have future utility in predicting disease outcome 
and informing treatment choice.  
 
Multiple groups have attempted to define clonal dynamics based on either lentiviral 
barcoding (cellular clones) or mutational clustering (genomic clones) by population and 
single cell based computational approaches (5,18).  For example, Eirew et al., 
reconstructed the genomic clonal dynamics of a panel of breast cancer PDX models using 
PyClone; a Bayesian clustering method for grouping somatic mutations (5). In each of the 
15 cases examined, clonal diversity was reduced by xenotransplantation. This varied from 
extreme engraftment bias, selecting minor clones present in the sample of origin, to only 
moderate clonal selection. Remarkably, similar clonal dynamics were observed in parallel 
xenografts established from the same sample. In a separate study, Ding et al., found PDX 
models established from a basal like breast cancer were more representative of the 
patient’s metastatic lesion than the primary tumour (19). These observations suggest 
deterministic mechanisms underline the clonal selection found on engraftment. Eirew et 
al., further observed variable clonal dynamics between PDXs established from different 
molecular subtypes; underscoring the need for better representation of tumour molecular 
subtypes (1,5). In summary, PDX models can at least partially recapitulate the complex 
clonal dynamics of human malignancies and engraftment biases may represent non-
stochastic selection events, which define a PDX model rather than limit its utility. The 
variable tumour- and subtype-dependent engraftment rates (low for some tumour types) 
and frequencies in the population mean that PDX programs representative of intertumour 
heterogeneity may require large multicentre collaborative efforts (such as the EuroPDX 
consortium (10)) and centralization of models.  
 
Clonal evolution is a continuous process, and may be substantially altered by the selective 
pressures applied during chemo- and targeted therapy. Coupled with spatial 
heterogeneity within the tumour this may result in the need for multiple-site repeat 
biopsies to decipher the clonal composition and dynamics of a tumour and inform 
treatment choice. Clearly these procedures will be highly invasive and may not be 
technically possible; it is with this in mind that many researchers have turned to liquid 
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biopsies (14,20). If our hypotheses are correct, modelling of clonal evolution in patient 
and matched PDX by computational approaches (such as PyClone (5) or CloneHD (18)) 
will allow unprecedented basic and translational research into clonal drivers of tumour 
progression and treatment response. Such studies will also be necessary to determine the 
longevity of PDX models of each cancer subtype, as it is unlikely that PDXs will remain 
patient-relevant and genomically stable in perpetuity.  
 
It has been proposed that aberrant DNA methylation patterns in cancer can blur the lines 
between distinct phenotypic ‘attractor states’ (21). Thus, it may be important to consider 
cellular clones as drivers of malignant progression, independent of their genetic 
background. To track these isogenic cellular clones, lentiviral tagging has been utilised to 
mark individual cells, and their progeny, in breast and colorectal PDX models (6,7). In an 
elegant study by Kreso et al., it was found that minor ‘type IV’ subclones in colorectal 
PDXs were able to repopulate the tumour bulk after treatment with chemotherapy (7). 
These quiescent cell populations were genetically similar to their highly proliferative 
counterparts, and were later linked to the BMI1+ population thought to act as reserve 
stem cells of the intestinal and colonic crypts (22). As the cellular clones defined in this 
study were isogenic, their phenotype may have been driven by microenvironmental cues 
capable of modulating cellular transition between distinct gene expression patterns or 
epigenetic attractor states (23). Hence, the microenvironment’s composition could 
profoundly alter both a cells propensity to malignancy and the heterogeneity we hope to 
preserve in PDX models. Regardless, we should not underestimate the significance of even 
a partial translation of vastly heterogeneous human diseases into experimental model 
systems.  
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Limitations of the PDX model: tumour-extrinsic sources of 
heterogeneity   
Aside from clonal dynamics driven by intrinsic differences in a cell’s genetic or epigenetic 
background, intratumour heterogeneity can be influenced by tumour-extrinsic factors in 
the non-cell-autonomous compartment (Figure 1A and Table 1) (23). Cellular interactions 
with the extracellular matrix (ECM) can alter gene expression programs, drive 
differentiation and profoundly alter cell behaviour. As cancers develop, tight regulation of 
the ECM is lost and tissue architecture begins to degrade (8). A recent study by Wang et 
al., provides direct evidence that ECM dependent signalling confers dynamic switching 
between TGFBR3 (transforming growth factor β receptor 3) and JUND (jun D proto-
oncogene) related expression signatures (24). ECM driven oscillations between signalling 
pathways such as those described could have profound effects on propensity to 
malignancy. Furthermore, solid state ECM interactions are necessary for cells to maintain 
stem cell properties and regulated ECM helps maintain the stem cell niche (25). As cancer 
is often associated with a blurring of the boundaries between stem and differentiated 
cells, it is possible that a loss of structured ECM is essential for the stability of multiple 
sub-dominant cellular clones within a tumour (21). In PDX models, MatrigelTM is often 
used to increase the engraftment efficiency, however it is worth noting that this is a 
murine basement membrane extract and suitable synthetic human alternatives are 
available. The presence of growth factors in Matrigel may favour the engraftment of one 
cell type over another. Finally, as ECM structure is tissue specific (25), researchers should 
consider the use of orthotopic transplantations where possible. 
The tumour microenvironment is further characterised by an influx of stromal cells. 
Infiltrating cancer associated fibroblasts (CAFs) can often confer resistance to cytotoxic 
and targeted therapies (9), however, recent studies confer on fibroblasts a degree of 
plasticity, with anti-tumour properties observed in some populations (26). Due to the 
high levels of CAF infiltrates seen in some tumour types, heterogeneity within their 
population would undoubtedly confer differential properties to the tumour bulk. We, and 
others, have found that human stromal cells are gradually replaced by murine equivalents 
upon engraftment in the mouse, suggesting that implanted human cells retain the ability 
to recruit murine accessory cells to their niche. However, it should be noted that some 
differences exist between ligand repertoires of human and murine fibroblasts (27). 
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Clearly stromal architecture and activity is mimicked in the murine host, however it is 
currently unclear how this reflects human stroma with regards supporting tumour 
growth and development.  
 
It is with this in mind that many have begun to investigate the co-engraftment of human 
mesenchymal stem cells (MSCs) or CAF cell lines in PDXs (Figure 1B and C). Here, care 
must be taken; the role of MSCs in tumour development is still controversial and may 
represent patient (or tissue) specific differences (28). If non-patient-matched sources of 
stromal cells are implanted, heterogeneity between tumours derived from different 
patients could be lost. Moreover, fibroblast cell lines vary considerably in their ability to 
confer resistance to cytotoxic therapies through hepatocyte growth factor (HGF)/c-Met 
signalling (9,27). Patient-derived fibroblasts can be isolated from tumour samples and 
expanded in vitro, thus, co-engraftment of matched stromal components should be 
considered wherever possible. This would significantly increase the advantages these 
models already have in retaining the complex heterogeneity found in patient samples.  
 
Considering the crucial role of the immune system in tumour progression, perhaps the 
most obvious disadvantage of PDX models is the necessity for severely immunodeficient 
host animals. Tumour cells are broadly thought to be antigenic: point mutations in coding 
exons in a developed tumour results in a large repertoire of neoantigens. Targeting of 
these neoantigens can lead to significant CD8+ cytotoxic T-cell infiltration and tumour cell 
death. However, most tumours eventually progress and evade the immune system - often 
through the dominant inhibitory effects of suppressive pathways (so called ‘immune 
checkpoints’ such as CTLA-4/B7 and PD-1/PD-L1). This is supported by the prognostic 
value of the CD8+ to FOXP3+ (Cytotoxic to Regulatory T-cell) ratio in many solid tumours, 
and the recently reported clinical efficacy of a variety of checkpoint inhibitors (29,30).  
 
The pro-inflammatory microenvironment established by CD8+ T-cells, M1 polarised 
tumour associated macrophages (TAMs), NK cells and others can lead to the recruitment 
of numerous immune suppressive components. TAMs and myeloid derived suppressor 
cells have been implicated in resistance to anti-angiogenic therapy. Additionally, 
macrophage and CD4+ T-cell recruitment following intensive chemotherapy in breast 
cancer patients is associated with significantly reduced recurrence free survival (30). 
Clearly, the co-engraftment of immune components into PDX models (Figure 1B) would 
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facilitate both the study of novel therapies targeting tumour-immune interactions and 
allow for basic research into patient specific cross-talk between tumour progression and 
immune surveillance. Clone or patient specific differences in tolerization of dendritic cells, 
macrophage and neutrophil polarity and regulatory T-cell (Treg) infiltration could 
provide multiple novel insights into tumour biology.  
 
The most robust reconstitution of the human immune system in immunodeficient mice is 
seen when bone marrow derived stem cells are co-engrafted along with liver and thymus 
fragments (BMT model) (31). However, the highly invasive multi-site biopsy required 
renders this model impractical for patient-matched humanised PDX models (huPDXs). 
CD34 marks a population of hematopoietic stem and progenitor cells (HSPCs) found in 
the blood and bone marrow. Mice implanted with CD34+ cells from umbilical cord blood 
show robust multilineage engraftment of human immune populations, though with 
reduced functionality relative to BMT mice. During chemotherapy, CD34+ cells leave the 
bone marrow and enter the circulation. If patients are given Granulocyte-Macrophage 
Colony Stimulating Factor (GM-CSF; LeukineTM) to aid recovery from chemotherapy, 
numbers of CD34+ cells in the circulation have been known to exceed the bone marrow 
itself.  Hence, CD34+ cells could potentially be harvested from patient’s blood to 
reconstitute a functional, patient-matched, immune system in mouse models (huCD34 
model). As such an immune system would mature in the mouse and human immune cells 
would undergo central tolerance to mouse antigens during development. However, as 
they would not be exposed to patient antigens during this process, it is likely that they 
would mount a rapid non-self response to any subsequently engrafted human tissue. One 
possible solution comes from a recent study by Cosgun et al., showing immunodeficient 
adult mice carrying a mutation in the Kit receptor could support robust, uniform and 
sustained engraftment of CD34+ cells (32). If patient-matched CD34+ HSPCs were 
engrafted in adult Kit mutant mice with an established PDX tumour, it is possible that a 
functional immune system could develop in the presence of both human and mouse 
antigens. 
 
The alternative, to engraft fully mature human immune cells, is used in the huPBMC 
model. Here, mononuclear cells from the peripheral blood (PBMCs) are isolated and 
implanted in immunodeficient mice. PBMCs comprise around 75% CD4/CD8+ T cells with 
the remainder primarily containing B and NK cells. As such, these models are well suited 
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to short-term experiments where lymphocyte function is of primary concern. Aside from 
the lifetime of circulating cells, the major limitation of the huPBMC model is the rapid 
onset of graft versus host disease (GVHD) as engrafted cells mount an immune response 
against host murine tissue. The onset of GVHD can be delayed somewhat by the use of 
NOD scid gamma (NSG) strains lacking MHC I (33).  
 
Undoubtedly the reconstitution of a patient-matched immune system in PDX models 
would be extremely valuable in the development of novel oncological drugs and in 
particular immunotherapeutics. The extent to which findings would be valid in the 
context of immune hyperactivation (against mouse in huPBMC or against tumour in 
huCD34) is unclear.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
 
Conclusions and future prospects – toward a huPDX model 
 
The PDX is arguably the most faithful model of cell-autonomous drivers of malignant 
progression. Sharing of expertise and resources through collaborative initiatives such as 
the EuroPDX consortium will lead to improved engraftment efficiencies and increase the 
breadth of tumour subtypes available in these model systems, contributing to a better 
representation of cancer heterogeneity in the lab (10).  
 
Cooperation and competition between genetically or phenotypically distinct subclonal 
populations is thought to drive tumour growth, resistance to therapy and recurrence. 
While cell-autonomous sources of heterogeneity are clearly recapitulated in PDX models, 
current techniques fail to properly account for non-cell-autonomous factors. The 
microenvironment has long been known to play a significant role in tumour progression, 
but an incomplete understanding of stromal influences makes co-engraftment of non-
patient-matched cell compartments a risky strategy. In order to maintain PDXs as models 
of diversity of human malignancies we must take care to engraft only patient-matched 
stromal components. CAFs have known roles in resistance to targeted therapy. It should, 
therefore, be a priority to ensure patient fibroblasts are maintained in the tumour 
xenograft.  
 
Reconstituting a patient-matched immune system in PDX models is a significant 
challenge. Standard methods of engrafting either CD34+ HSPCs or mature circulating 
PBMCs will likely lead to inappropriate immune responses against human or murine 
tissues respectively. In order to study long-term tumour-immune interactions, a 
reconstituted immune system must simultaneously maintain tolerance to its human 
donor and acquire tolerance to its new host. A solution could come from engrafting both 
mature and naïve cell types. Maturing cells in the thymus and bone marrow would 
acquire central tolerance to murine tissues whilst mature cells in the periphery could act 
to suppress inappropriate responses against human antigens.  
 
PDX models are capable of recapitulating the complexity of human malignancy 
remarkably well. These models have extraordinary utility in basic cancer research and 
beyond this have demonstrated clinical predictive power, allowing multiplexed screening 
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of novel therapeutics in vivo. However, the aforementioned limitations of this model must 
be carefully considered when interpreting data. Although a significant amount of research 
is still needed, patient-matched huPDX models with co-engrafted stromal and immune 
components would offer unprecedented opportunity to study tumour biology and would 
be invaluable models in oncological drug development. In the future, huPDX models could 
allow researchers and clinicians to both predict and explain tumour response to novel 
targeted therapies.  
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Figure Legend  
 
Figure 1 A shows a primary breast tumour including some sources of heterogeneity found 
in the native microenvironment. Reciprocal signalling pathways between tumour cells 
and tumour associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are 
highlighted. Extracellular matrix (ECM) is shown as collagen fibres with associated 
fibroblasts and macrophage/dendritic cells with T/B Lymphocytes are shown as part of 
the immune infiltrate, though other cell types (NK cells, myeloid derived suppressors etc.) 
have been omitted for simplicity.  
Panel B highlights patient matched fibroblasts and immune cells as possible candidates 
for co-engraftment in the next generation of PDX models. Current PDXs established in 
NSG mice lack an adaptive immune system and may have impaired innate immune cell 
infiltrates and cytokine signalling due to defective IL-2 receptor (33). Cancer associated 
fibroblasts are known to contribute to treatment response, although murine fibroblasts 
are present in PDX models, it is unclear how faithfully these recapitulate their human 
counterparts (26). 
Panel C shows a PDX tumour in its native microenvironment. Questions over whether 
pro- and anti- tumour CAF/TAM signalling pathways are present to the same extent in 
PDX models as in the primary tumour are highlighted. Stromal and tissue architecture can 
have profound effects on transcriptional regulation but are often overlooked in the 
establishment of PDX models (25). To highlight potential differences in ECM organisation 
between the native microenvironment and that of the PDX, here the ECM is shown as 
highly organised collagen fibres with closely associated myofibroblasts. 
 
 
Table Legend  
 
Table 1 shows sources of tumour heterogeneity, their consequences in translational and 
basic cancer biology and how they are currently represented in PDX models. Strategies to 
improve the model, by better representation of both cell-autonomous (genomic and 
epigenomic clones etc.) and non-cell-autonomous (stroma, immune infiltrate etc.) drivers 
of heterogeneity are proposed.  
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